Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452802 · ClinicalTrials.gov registry record
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management
A clinical trial of Heart Failure, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT01452802: Completed study of Heart Failure, sponsored by Abbott Medical Devices.
NCT01452802 is a study of Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 200 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01452802, a study of Heart Failure, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate and compare the effectiveness of the HeartMate II (HM II) Left Ventricular Assist Device (LVAD) support versus OMM in ambulatory NYHA Class IIIB/IV heart failure patients who are not dependent on intravenous inotropic support and who meet the FDA approved indications for HM II LVAD destination therapy.
Conditions Studied
Interventions
- DEVICE HM II (HeartMate II LVAD)
- DRUG OMM (Optimal Medical Management)
Study Locations (20)
California
- Cedars Sinai Medical Center - Beverly Hills
- Keck Medical Center of USC - Los Angeles
- Sharp Memorial Hospital - San Diego
- Stanford University - Stanford
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
- University of Minnesota Medical Center - Minneapolis
- Mayo Clinic Rochester - Rochester
Florida
- Shands Hospital at University of Florida - Gainesville
- Tampa General Hospital - Tampa
Georgia
- Emory University Hospital - Atlanta
- St. Joseph's Hospital / Atlanta - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
- Advocate Christ Medical Center - Oak Lawn
Michigan
- Henry Ford Hospital - Detroit
- Michigan Heart - Ypsilanti
Arkansas
- Baptist Medical Center - Little Rock
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-06 |
What the finished NCT01452802 record still lists
NCT01452802 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which HM II (HeartMate II LVAD) is the first listed.
NCT01452802 names 20 study sites across 11 states, led by California, Minnesota, Florida.
Frequently Asked Questions
What is clinical trial NCT01452802 about?
NCT01452802 is a clinical study titled "Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management". The purpose of this study is to evaluate and compare the effectiveness of the HeartMate II (HM II) Left Ventricular Assist Device (LVAD) support versus OMM in ambulatory NYHA Class IIIB/IV heart failure patients who are not dependent on intravenous inotropic support and who meet the FDA approved ind...
What is the current status of trial NCT01452802?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2011-10. Estimated completion is 2016-06.
What conditions does trial NCT01452802 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01452802?
The interventions under investigation include: HM II (HeartMate II LVAD) (DEVICE), OMM (Optimal Medical Management) (DRUG).
Who is sponsoring clinical trial NCT01452802?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01452802 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01452802's enrollment target sits among peer trials
200 165th of 397 higher than 229 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia